214 related articles for article (PubMed ID: 19047281)
1. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Dawood S; Broglio K; Kau SW; Green MC; Giordano SH; Meric-Bernstam F; Buchholz TA; Albarracin C; Yang WT; Hennessy BT; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2009 Jan; 27(2):220-6. PubMed ID: 19047281
[TBL] [Abstract][Full Text] [Related]
2. Does race predict survival for women with invasive breast cancer?
Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
Chavez-Macgregor M; Litton J; Chen H; Giordano SH; Hudis CA; Wolff AC; Valero V; Hortobagyi GN; Bondy ML; Gonzalez-Angulo AM
Cancer; 2010 Sep; 116(17):4168-77. PubMed ID: 20564153
[TBL] [Abstract][Full Text] [Related]
4. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
5. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
Balmanoukian A; Zhang Z; Jeter S; Slater S; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Davidson NE; Jacobs L; Lange J; Tsangaris TN; Zellars R; Gabrielson E; Stearns V
J Clin Oncol; 2009 Aug; 27(22):e35-7; author reply e38-9. PubMed ID: 19564528
[No Abstract] [Full Text] [Related]
6. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
8. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
[TBL] [Abstract][Full Text] [Related]
9. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Raphael J; Kiss A; Nofech-Mozes S; Trudeau M
Clin Breast Cancer; 2018 Dec; 18(6):e1381-e1387. PubMed ID: 30122349
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases].
Guan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):196-9. PubMed ID: 18756935
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy.
Asaga S; Kinoshita T; Hojo T; Suzuki J; Jimbo K; Tsuda H
Clin Breast Cancer; 2013 Feb; 13(1):40-6. PubMed ID: 23103363
[TBL] [Abstract][Full Text] [Related]
16. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
[TBL] [Abstract][Full Text] [Related]
17. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
